Clinical Trial Update: FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of FGF401 in hepatocellular carcinoma and other solid tumors characterized by FGFR4 and KLB expression has completed. Results were posted 2020-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Solid Tumors

Drugs mentioned

• FGF401 (FGF401)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatocellular Carcinoma (HCC), Solid Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-17